Search

Your search keyword '"Dantal J."' showing total 445 results
Start Over Author "Dantal J."

Refine your results

more »

more »

more »

more »
445 results on '"Dantal J."'

60. Serum levels of macrophage-colony stimulating factor (M-CSF): A marker of kidney allograft rejection.

Author

Praloran V., Mons S., Jose M., Dantal J., Lemauff B., Aldigier J.-C., Leroux-Robert C., Le Meur Y., Leprivey-Lorgeot V., Praloran V., Mons S., Jose M., Dantal J., Lemauff B., Aldigier J.-C., Leroux-Robert C., Le Meur Y., and Leprivey-Lorgeot V.

Abstract

Background. Macrophage-colony stimulating factor (M-CSF) is the principal factor for survival of monocytes and macrophages that play an important role in allograft rejection. We studied M-CSF serum levels during successful renal transplantation and acute graft rejection. Methods. A total of 114 kidney allograft recipients were assessed for M-CSF levels by enzyme-linked immunosorbent assay (ELISA). Results. M-CSF serum levels were elevated in pretransplant haemodialysis patients (611+/-355 IU/ml vs 168+/-61 in normal controls, P<0.01). Following successful renal transplantation, M-CSF decreased in the first month, stabilizing at 257+/-222IU/ml (not significantly different from normal controls) in 52 post-transplant stable patients. There was no correlation between M-CSF level and creatinine clearance. M-CSF levels increased significantly (2-5 times) during biopsy-proven acute rejection episodes in 20 of 25 patients. All rejection episodes were successfully treated and serum M-CSF decreased rapidly to pre-rejection levels in 17/20 patients. In contrast, in five patients with cyclosporin toxicity and four patients with other causes of allograft dysfunction, M-CSF serum levels did not change. Conclusions. M-CSF serum level might be a specific marker of acute rejection. The source of increased production during rejection warrants further investigation, with infiltrating T cells and resident kidney cells being likely candidates. © ERA-EDTA 2004; all rights reserved.

Published
2012

65. [Post-transplantation of Hodgkin's disease. Clinico-pathologic study of 3 cases]

Author

Moreau A, Dantal J, Mf, Heymann, Gaillard F, Dubigeon P, Portier D, Moreau P, Noel Milpied, and Laboisse C

Subjects
Adult, Immunosuppression Therapy, Male, Herpesvirus 4, Human, Heart Transplantation, Humans, Transplantation, Homologous, Middle Aged, Hodgkin Disease, Immunohistochemistry, Kidney Transplantation
Abstract

As a frequent complication of immunosuppression, lymphoproliferative disorders affect approximately 2 % of allorgan transplant recipients. Most of them are EBV-associated-B-cell-lymphoproliferations. Other types of non Hodgkin's lymphomas and Hodgkin's disease, as observed in general population, have only rarely been reported in this group of patients. We report three cases of Hodgkin's disease, which were diagnosed in two renal transplant recipients and one heart transplant patient. They were associated with Epstein-Barr virus, as demonstrated by immunohistochemistry and in situ hybridization. EBV is frequently associated with Hodgkin's disease in the general population, and always implicated in AIDS-related Hodgkin's disease. However in transplant patients the rarity of Hodgkin's disease argues against a direct oncogenic role of this virus.

Published
1996

73. A PROSPECTIVE MULTICENTER OPEN-LABEL RANDOMIZED STUDY TO ASSESS EFFICACY AND SAFETY OF EVEROLIMUS WITH CICLOSPORINE-MICROEMULSION (CSA-ME) VERSUS EVEROLIMUS WITHOUT CALCINEURINE INHIBITOR WITH MYCOPHENOLATE SODIUM, IN MAINTENANCE ADULT KIDNEY TRANSPLANT PATIENTS: FOREVER STUDY

Author

CASSUTO, E., primary, Berthoux, F., additional, TOUPANCE, O., additional, MOULIN, B., additional, MOAL, M. C., additional, QUERE, S., additional, CHAOUCHE-TEYARA, K., additional, and Dantal, J., additional

Published
2010
Full Text
View/download PDF

79. Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance

Author

Campistol, J. M., primary, Albanell, J., additional, Arns, W., additional, Boletis, I., additional, Dantal, J., additional, de Fijter, J. W., additional, Mortensen, S. A., additional, Neumayer, H.-H., additional, Oyen, O., additional, Pascual, J., additional, Pohanka, E., additional, Schena, F. P., additional, Seron, D., additional, Sparacino, V., additional, and Chapman, J. R., additional

Published
2007
Full Text
View/download PDF

98. Potential role of soluble ST2 protein in idiopathic nephrotic syndrome recurrence following kidney transplantation.

Author

Bruneau S, Le Berre L, Hervé C, Valanciuté A, Kamal M, Naulet J, Tesson L, Foucher Y, Soulillou JP, Sahali D, Dantal J, Bruneau, Sarah, Le Berre, Ludmilla, Hervé, Caroline, Valanciuté, Asta, Kamal, Maud, Naulet, Jeanne, Tesson, Laurent, Foucher, Yohann, and Soulillou, Jean-Paul

Abstract

Background: Corticosteroid-resistant idiopathic nephrotic syndrome (INS) recurs rapidly after transplantation in 30% to 50% of transplant recipients, suggesting the presence of 1 or more circulating factors that alter the glomerular filtration barrier. We investigated the possible role in INS recurrence of soluble ST2 (sST2) protein, a marker of T helper type 2 (T(H)2) cells and a factor predicted to be regulated by the transcription factor c-Maf; involvement of sST2 protein would be consistent with the observation that both T(H)2 cells and c-Maf appear to be activated during INS relapse. Study Design: Retrospective observational study. Setting& Participants: Patients with biopsy-proven corticosteroid-resistant INS who had undergone kidney transplantation between September 1983 and April 2007 (n = 71). A control group consisting of proteinuric transplant recipients with kidney failure unrelated to INS (n = 34). Predictor: Patients who developed INS recurrence after transplantation (n = 31) were compared with those in whom INS did not recur (n = 40) and the control group. Recurrence of INS was defined as urine protein excretion greater than 2 g/d immediately after transplantation that persisted at greater than 1 g/d despite treatment or a kidney graft biopsy showing minimal change glomerulonephritis or focal segmental glomerulosclerosis. Outcomes& Measurements: Urine protein excretion in the 3 groups was 5.0 g/d (range, 1.3 to 10.5), 0.14 g/d (range, 0 to 0.46), and 4.3 g/d (range, 3 to 6.2). The sST2 protein was analyzed both quantitatively and qualitatively in patient sera, and its activity was tested in vitro on a mouse podocyte cell line and in vivo in rats. Results: sST2 protein levels were significantly increased after transplantation in patients with INS recurrence compared with the 2 other groups (617.5 versus 23 pg/mL; P < 0.001 and 158.5 pg/mL; P < 0.01 respectively). However, patients with recurrence expressed a normal sST2 isoform, and the sST2 protein was unable to induce podocyte injury in vitro or trigger proteinuria in rats. Limitations: Pretransplantation and posttransplantation sera do not always represent paired samples. Conclusions: These data suggest that sST2 protein is a marker of INS recurrence that does not seem to be involved in the development of INS. [ABSTRACT FROM AUTHOR]

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results